DK175206B1 - Ekspressionskontrolsekvenser - Google Patents
Ekspressionskontrolsekvenser Download PDFInfo
- Publication number
- DK175206B1 DK175206B1 DK198603206A DK320686A DK175206B1 DK 175206 B1 DK175206 B1 DK 175206B1 DK 198603206 A DK198603206 A DK 198603206A DK 320686 A DK320686 A DK 320686A DK 175206 B1 DK175206 B1 DK 175206B1
- Authority
- DK
- Denmark
- Prior art keywords
- dna sequence
- promoter
- gram
- expression control
- expression
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 107
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 62
- 239000013604 expression vector Substances 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000005030 transcription termination Effects 0.000 claims abstract description 26
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 238000013518 transcription Methods 0.000 claims abstract description 17
- 230000035897 transcription Effects 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000013612 plasmid Substances 0.000 claims description 74
- 108020004414 DNA Proteins 0.000 claims description 69
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 56
- 241000588724 Escherichia coli Species 0.000 claims description 37
- 230000001580 bacterial effect Effects 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 28
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 19
- 108091026890 Coding region Proteins 0.000 claims description 19
- 108091008146 restriction endonucleases Proteins 0.000 claims description 19
- 239000013605 shuttle vector Substances 0.000 claims description 19
- 230000000977 initiatory effect Effects 0.000 claims description 9
- 230000003362 replicative effect Effects 0.000 claims description 8
- 244000063299 Bacillus subtilis Species 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 6
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 4
- 238000012270 DNA recombination Methods 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 4
- 241000701988 Escherichia virus T5 Species 0.000 claims description 3
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 claims description 3
- 239000013599 cloning vector Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 241000701867 Enterobacteria phage T7 Species 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 230000005026 transcription initiation Effects 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 31
- 229960005091 chloramphenicol Drugs 0.000 description 31
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 31
- 239000012634 fragment Substances 0.000 description 31
- 238000001962 electrophoresis Methods 0.000 description 25
- 238000010276 construction Methods 0.000 description 24
- 108020001507 fusion proteins Proteins 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 20
- 239000011543 agarose gel Substances 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 16
- 229960005542 ethidium bromide Drugs 0.000 description 16
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- 229920000936 Agarose Polymers 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 239000006142 Luria-Bertani Agar Substances 0.000 description 10
- 229930027917 kanamycin Natural products 0.000 description 10
- 229960000318 kanamycin Drugs 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 8
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 8
- 108020005038 Terminator Codon Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 101150055766 cat gene Proteins 0.000 description 7
- 101000897961 Rattus norvegicus Endothelial cell-specific molecule 1 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000297434 Stenotarsus subtilis Species 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 3
- 108010022394 Threonine synthase Proteins 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- FTMJFHVKAXPFIY-RKDXNWHRSA-N 2,2-dichloro-n-[(1r,2r)-1,3-dihydroxy-1-(3-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=CC([N+]([O-])=O)=C1 FTMJFHVKAXPFIY-RKDXNWHRSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 101100323157 Arabidopsis thaliana LAP1 gene Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 1
- 101000579218 Homo sapiens Renin Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 101100115246 Rattus norvegicus Cx3cr1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108010070718 kanamycin nucleotidyltransferase Proteins 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108091007054 readthrough proteins Proteins 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/832—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/848—Escherichia
- Y10S435/849—Escherichia coli
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8517071 | 1985-07-05 | ||
| GB858517071A GB8517071D0 (en) | 1985-07-05 | 1985-07-05 | Gram-positive expression control sequence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK320686D0 DK320686D0 (da) | 1986-07-04 |
| DK320686A DK320686A (da) | 1987-01-06 |
| DK175206B1 true DK175206B1 (da) | 2004-07-12 |
Family
ID=10581857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198603206A DK175206B1 (da) | 1985-07-05 | 1986-07-04 | Ekspressionskontrolsekvenser |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4868111A (fr) |
| EP (1) | EP0207459B1 (fr) |
| JP (2) | JP2632809B2 (fr) |
| AT (1) | ATE62020T1 (fr) |
| AU (1) | AU594349B2 (fr) |
| CA (1) | CA1316850C (fr) |
| DE (1) | DE3678343D1 (fr) |
| DK (1) | DK175206B1 (fr) |
| GB (1) | GB8517071D0 (fr) |
| IE (1) | IE59165B1 (fr) |
| IL (1) | IL79291A (fr) |
| NZ (1) | NZ216688A (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266474A (en) * | 1987-06-24 | 1993-11-30 | Genentech, Inc. | Balanced inducible transcription system |
| ATE123526T1 (de) * | 1987-08-17 | 1995-06-15 | Hoffmann La Roche | Hochreprimierbare expressionskontrollsequenzen. |
| US5726042A (en) * | 1988-04-07 | 1998-03-10 | Abbott Laboratories | Expression of heterologous proteins in Bacillus megaterium utilizing sporulation promoters of Bacillus subtilis |
| GB8811761D0 (en) * | 1988-05-18 | 1988-06-22 | Thomae Gmbh Dr K | Biosynthetic process for preparation of chemical compounds |
| US7049102B1 (en) | 1989-09-22 | 2006-05-23 | Board Of Trustees Of Leland Stanford University | Multi-gene expression profile |
| FR2679568B1 (fr) * | 1991-07-22 | 1994-09-02 | Pasteur Institut | Nouveau type de replicon gram-positif - construction de vecteurs recombinants le contenant. |
| WO1993017117A1 (fr) | 1992-02-27 | 1993-09-02 | Lynxvale Limited | Expression de genes heterologues dans lactococcus et produits d'expression obtenus |
| US6022730A (en) * | 1994-06-17 | 2000-02-08 | Robinson; Douglas H. | Methods for the isolation of bacteria containing eukaryotic genes |
| US5629205A (en) * | 1995-05-19 | 1997-05-13 | Allelix Biopharmaceuticals Inc. | Promoters for gene expression |
| US6194168B1 (en) | 1997-09-30 | 2001-02-27 | Human Genome Sciences, Inc. | Expression control sequences |
| US6146848A (en) * | 1998-07-23 | 2000-11-14 | The Hong Kong University Of Science & Technology | Bacterial expression system |
| US6720174B1 (en) | 1999-01-28 | 2004-04-13 | Novozymes A/S | Phytases |
| EP2502998A3 (fr) * | 1999-04-09 | 2013-02-27 | Intercell USA, Inc. | Vaccin à toxine recombinante A/B contre Clostridium difficile |
| ATE474932T1 (de) * | 2000-10-25 | 2010-08-15 | Fujifilm Corp | Methode zur analyse doppelsträngiger dna |
| AU2002365223A1 (en) * | 2001-10-26 | 2003-09-02 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| CN1906294B (zh) | 2003-11-19 | 2013-09-11 | 陶氏环球技术公司 | 改良的蛋白表达系统 |
| AU2004317306B2 (en) | 2003-11-21 | 2010-09-02 | Pelican Technology Holdings, Inc. | Improved expression systems with Sec-system secretion |
| KR101183720B1 (ko) | 2004-01-16 | 2012-09-17 | 다우 글로벌 테크놀로지스 엘엘씨 | 슈도모나스 플루오레센스에서의 포유류 단백질의 발현 |
| JP2008507294A (ja) | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
| GB0602173D0 (en) * | 2006-02-03 | 2006-03-15 | Avecia Ltd | Expression system |
| JP5323707B2 (ja) | 2006-10-18 | 2013-10-23 | ペリネス リミテッド | 男性の生殖能力低下の診断および治療のための方法ならびに薬理学的組成物 |
| EP2108047B1 (fr) | 2007-01-31 | 2012-10-24 | Pfenex Inc. | Sequences leader bacteriennes pour augmenter l'expression |
| EP2142651B1 (fr) | 2007-04-27 | 2013-05-22 | Pfenex Inc. | Procédé pour rapidement cribler des hôtes microbiens et identifier certaines souches ayant un rendement et/ou une qualité d'expression des protéines hétérologues améliorés |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| WO2010132341A2 (fr) | 2009-05-11 | 2010-11-18 | Pfenex, Inc. | Production de protéine de recombinaison faisant intervenir des méthodes de sélection non antibiotiques et l'incorporation d'acides aminés non naturels |
| RU2573909C2 (ru) | 2010-03-04 | 2016-01-27 | Пфенекс Инк. | Способ получения растворимого рекомбинантного белка интерферона без денатурирования |
| WO2011126811A2 (fr) | 2010-03-30 | 2011-10-13 | Pfenex Inc. | Expression de protéines de toxines recombinantes en forte quantité |
| AU2011235210B2 (en) | 2010-04-01 | 2015-07-16 | Pfenex Inc. | Methods for G-CSF production in a Pseudomonas host cell |
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| US11408007B2 (en) | 2014-09-26 | 2022-08-09 | Yale University | Compositions and methods for biocontainment of microorganisms |
| MX2017006866A (es) | 2014-12-01 | 2017-11-15 | Pfenex Inc | Pares de unión para producción de péptidos. |
| AU2018354069A1 (en) | 2017-10-27 | 2020-06-11 | Pelican Technology Holdings, Inc. | Bacterial leader sequences for periplasmic protein expression |
| EP3700921A4 (fr) | 2017-10-27 | 2021-12-15 | Pfenex Inc. | Procédé de production d'erwinia asparaginase de recombinaison |
| US11149280B2 (en) | 2019-10-29 | 2021-10-19 | Yale University | Engineering organisms resistant to viruses and horizontally transferred genetic elements |
| WO2022211829A1 (fr) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosage de l-asparaginase recombinante |
| WO2023178316A2 (fr) | 2022-03-17 | 2023-09-21 | Yale University | Compositions et méthodes d'expression d'éléments génétiques synthétiques chez divers micro-organismes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4495280A (en) * | 1981-05-20 | 1985-01-22 | The Board Of Trustees Of The Leland Stanford Jr. University | Cloned high signal strength promoters |
| GR81701B (fr) | 1983-01-18 | 1984-12-12 | Lilly Co Eli | |
| EP0115936A1 (fr) * | 1983-01-24 | 1984-08-15 | Kabushiki Kaisha Yakult Honsha | Plasmides chimériques |
-
1985
- 1985-07-05 GB GB858517071A patent/GB8517071D0/en active Pending
-
1986
- 1986-06-17 US US07/875,437 patent/US4868111A/en not_active Expired - Fee Related
- 1986-06-27 AT AT86108774T patent/ATE62020T1/de not_active IP Right Cessation
- 1986-06-27 EP EP86108774A patent/EP0207459B1/fr not_active Expired - Lifetime
- 1986-06-27 DE DE8686108774T patent/DE3678343D1/de not_active Expired - Lifetime
- 1986-06-27 NZ NZ216688A patent/NZ216688A/xx unknown
- 1986-06-30 IL IL79291A patent/IL79291A/xx not_active IP Right Cessation
- 1986-06-30 AU AU59385/86A patent/AU594349B2/en not_active Expired
- 1986-07-04 JP JP61157771A patent/JP2632809B2/ja not_active Expired - Lifetime
- 1986-07-04 IE IE180686A patent/IE59165B1/en not_active IP Right Cessation
- 1986-07-04 CA CA000513094A patent/CA1316850C/fr not_active Expired - Lifetime
- 1986-07-04 DK DK198603206A patent/DK175206B1/da not_active IP Right Cessation
-
1996
- 1996-07-16 JP JP8185740A patent/JP2887248B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL79291A (en) | 1991-06-30 |
| CA1316850C (fr) | 1993-04-27 |
| EP0207459A2 (fr) | 1987-01-07 |
| JPH10229878A (ja) | 1998-09-02 |
| EP0207459A3 (en) | 1988-07-06 |
| IE861806L (en) | 1987-01-05 |
| NZ216688A (en) | 1990-06-26 |
| DK320686D0 (da) | 1986-07-04 |
| IL79291A0 (en) | 1986-09-30 |
| AU5938586A (en) | 1987-01-08 |
| GB8517071D0 (en) | 1985-08-14 |
| DE3678343D1 (de) | 1991-05-02 |
| EP0207459B1 (fr) | 1991-03-27 |
| AU594349B2 (en) | 1990-03-08 |
| IE59165B1 (en) | 1994-01-12 |
| JP2887248B2 (ja) | 1999-04-26 |
| DK320686A (da) | 1987-01-06 |
| US4868111A (en) | 1989-09-19 |
| JP2632809B2 (ja) | 1997-07-23 |
| JPS6214786A (ja) | 1987-01-23 |
| ATE62020T1 (de) | 1991-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175206B1 (da) | Ekspressionskontrolsekvenser | |
| Kaster et al. | Analysis of a bacterial hygromycin B resistance gene by transcriptional and translational fusions and by DNA sequencing | |
| Baty et al. | Extracellular release of colicin A is non‐specific. | |
| EP0410655A1 (fr) | Contrôle de l'expression de gènes hétérologues de promoteurs opérés par lac | |
| Hamilton et al. | Structure of genes and an insertion element in the methane producing archaebacterium Methanobrevibacter smithii | |
| WO1997014805A2 (fr) | Procede de production de plasmides de recombinaison | |
| US5232841A (en) | Expression vectors containing a bacillus brevis signal sequence | |
| Ishino et al. | Nucleotide sequence of the lig gene and primary structure of DNA ligase of Escherichia coli | |
| US5726039A (en) | Vectors and transformed host cells for recombinant protein production at reduced temperatures | |
| Kovacevic et al. | Secretion of staphylococcal nuclease by Bacillus subtilis | |
| Schottel et al. | Effects of alterations in the translation control region on bacterial gene expression: use of cat gene constructs transcribed from the lac promoter as a model system | |
| EP0821063B1 (fr) | Production améliorée de riboflavine | |
| JPS62181789A (ja) | バチルスの制御領域のクロ−ニング及び解析のためのプラスミド | |
| US7868148B2 (en) | Plasmids, their derivatives and fragments, their methods of manufacture and application | |
| US6617130B1 (en) | DNA construct for regulating the expression of a polypeptide coding sequence in a transformed bacterial host cell | |
| Ludtke et al. | Identification of the phoM gene product and its regulation in Escherichia coli K-12 | |
| Shimizu et al. | Identification of the promoter region of the ribosome-releasing factor cistron (frr) | |
| Zaghloul et al. | Translational coupling in Bacillus subtilis of a heterologous Bacillus subtilis-Escherichia coli gene fusion | |
| US5654169A (en) | Vectors and transformed host cells for recombinant protein production at reduced temperatures | |
| EP0186069B1 (fr) | Séquence de contrôle d'expression | |
| EP0182562B1 (fr) | Procédé pour pouvoir exprimer par induction thermique un gène dans des bactéries gram-positives, souches de bacillus subtilis contenant des plasmides, qui induisent une telle expression et systèmes de vecteurs portables | |
| US5212083A (en) | Sequence for stabilizing proteins in bacteria | |
| Birkmann et al. | Construction of chimaeric promoter regions by exchange of the upstream regulatory sequences from fdhF and nif genes | |
| HU197595B (en) | Process for producing expression vectors | |
| Brevet et al. | Tn 7-encoded proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |